A diabetes drug may soon double as a treatment for liver disease. Dapagliflozin, an SGLT-2 inhibitor typically used for type ...

A recent Chinese clinical trial published in The BMJ reveals that dapagliflozin, a type 2 diabetes drug, shows promise in ...

For patients with metabolic dysfunction-associated steatohepatitis (MASH), treatment with dapagliflozin is beneficial for ...

The sodium glucose cotransporter 2 (SGLT-2) inhibitor drug dapagliflozin, widely used to treat type 2 diabetes, also shows ...

A diabetes drug, dapagliflozin, has shown promise in treating fatty liver disease by reducing liver fat and scarring, ...

Improves fibrosis and steatohepatitis Metabolic dysfunction-associated steatotic liver disease (MASLD) encompasses a broad clinical spectrum, ranging from simple steatosis to metabolic ...

Dapagliflozin improved metabolic dysfunction-associated steatohepatitis (MASH) without worsening fibrosis in a randomized trial in China. The study included younger patients who were predominantly ...

Dapagliflozin propanediol is a sodium-glucose co-transporter-2 (SGLT2) inhibitor used to treat type 2 diabetes, heart failure, and chronic kidney disease. By reducing glucose reabsorption in the ...

SAN DIEGO — Dapagliflozin provides significant benefits in the treatment of chronic kidney disease (CKD) even when initiated in patients with the most severe stages of the disease who are ...

Patients with chronic kidney disease (CKD), whether or not they also had diabetes, were found to have a reduced risk of hospitalization when they took dapagliflozin. Among patients with chronic ...